200 related articles for article (PubMed ID: 27609563)
41. Aspergillus Mediastinitis after Orthotopic Heart Transplantation: A Case Report.
El-Sayed Ahmed MM; Almanfi A; Aftab M; Singh SK; Mallidi HR; Frazier OH
Tex Heart Inst J; 2015 Oct; 42(5):468-70. PubMed ID: 26504444
[TBL] [Abstract][Full Text] [Related]
42. Clinical Features and Survival Outcomes of Invasive Aspergillosis in Pediatric Patients at a Medical School in Thailand.
Anugulruengkitt S; Trinavarat P; Chantranuwat P; Sritippayawan S; Pancharoen C; Thanyawee P
J Med Assoc Thai; 2016 Feb; 99(2):150-8. PubMed ID: 27249894
[TBL] [Abstract][Full Text] [Related]
43. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus.
Dotis J; Roilides E
Int J Infect Dis; 2004 Mar; 8(2):103-10. PubMed ID: 14732328
[TBL] [Abstract][Full Text] [Related]
44. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
45. Clinical evaluation of 61 patients with pulmonary aspergilloma.
Kawamura S; Maesaki S; Tomono K; Tashiro T; Kohno S
Intern Med; 2000 Mar; 39(3):209-12. PubMed ID: 10772121
[TBL] [Abstract][Full Text] [Related]
46. [Aspergillus spondylodiscitis. Apropos of 5 cases].
Cortet B; Deprez X; Triki R; Savage C; Flipo RM; Duquesnoy B; Delcambre B
Rev Rhum Ed Fr; 1993 Jan; 60(1):37-44. PubMed ID: 8242025
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
48. Invasive Aspergillus sinusitis in pediatric bone marrow transplant patients. Evaluation and management.
Choi SS; Milmoe GJ; Dinndorf PA; Quinones RR
Arch Otolaryngol Head Neck Surg; 1995 Oct; 121(10):1188-92. PubMed ID: 7546589
[TBL] [Abstract][Full Text] [Related]
49. Pediatric aspergillosis: disease and treatment differences in children.
Steinbach WJ
Pediatr Infect Dis J; 2005 Apr; 24(4):358-64. PubMed ID: 15818297
[TBL] [Abstract][Full Text] [Related]
50. Primary cutaneous Aspergillus ustus infection: second reported case.
Ricci RM; Evans JS; Meffert JJ; Kaufman L; Sadkowski LC
J Am Acad Dermatol; 1998 May; 38(5 Pt 2):797-8. PubMed ID: 9591788
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.
Kirkpatrick WR; McAtee RK; Fothergill AW; Loebenberg D; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2000 Mar; 44(3):780-2. PubMed ID: 10681359
[TBL] [Abstract][Full Text] [Related]
52. Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach.
Duchini A; Redfield DC; McHutchison JG; Brunson ME; Pockros PJ
South Med J; 2002 Aug; 95(8):897-9. PubMed ID: 12190228
[TBL] [Abstract][Full Text] [Related]
53. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies.
Reinwald M; Hummel M; Kovalevskaya E; Spiess B; Heinz WJ; Vehreschild JJ; Schultheis B; Krause SW; Claus B; Suedhoff T; Schwerdtfeger R; Reuter S; Kiehl MG; Hofmann WK; Buchheidt D
J Antimicrob Chemother; 2012 Sep; 67(9):2260-7. PubMed ID: 22740590
[TBL] [Abstract][Full Text] [Related]
54. Aspergillus fumigatus cranial infection after accidental traumatism.
Rodríguez-Hernández MJ; Jiménez-Mejías ME; Montero JM; Regordan C; Ferreras G
Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):655-6. PubMed ID: 11714049
[TBL] [Abstract][Full Text] [Related]
55. Species distribution and antifungal susceptibility of
Osman M; Bidon B; Abboud C; Zakaria A; Hamze B; Achcar ME; Mallat H; Dannaoui E; Dabboussi F; Papon N; Bouchara JP; Hamze M
Future Microbiol; 2021 Jan; 16(1):13-26. PubMed ID: 33438473
[No Abstract] [Full Text] [Related]
56. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
57. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B.
Ozsahin H; von Planta M; Müller I; Steinert HC; Nadal D; Lauener R; Tuchschmid P; Willi UV; Ozsahin M; Crompton NE; Seger RA
Blood; 1998 Oct; 92(8):2719-24. PubMed ID: 9763555
[TBL] [Abstract][Full Text] [Related]
58. Aspergillus flavus Keratitis: Experience of a Tertiary Eye Clinic in Turkey.
Erdem E; Yagmur M; Boral H; Ilkit M; Ersoz R; Seyedmousavi S
Mycopathologia; 2017 Apr; 182(3-4):379-385. PubMed ID: 27826683
[TBL] [Abstract][Full Text] [Related]
59. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
60. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.
Chandrasekar PH; Ito JI
Clin Infect Dis; 2005 May; 40 Suppl 6():S392-400. PubMed ID: 15809925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
